Skyrizi: how long were the pivotal tox studies?

“BI 655066: A 26-Week subcutaneous toxicity and toxicokinetics study in Cynomolgus monkeys with an 8-week recovery period”

“Repeat dose toxicity of risankizumab was evaluated in a four-week study after IV administration of up to 50 mg/kg/week and at 20 mg/kg/week after SC administration, and in a 26 week chronic study with subcutaneous doses of up to 50 mg/kg/week.”

“Repeat dose toxicity of risankizumab was evaluated in a four-week study after IV administration of up to 50 mg/kg/week and at 20 mg/kg/week after SC administration”